Parp Breast Cancer
Parp clinical trials have recently been testing the use of breast cancer inhibitors such as BSI 201 and Olaparib. What these trials have found is that the drugs are very effective in treating metastatic breast cancer, they affect the parp breast cancer cells by altering their ability to replicate DNA and grow. This study of breast cancer trials was presented at ASCO in June 2009 and whilst it was a small study the results showed significant improvements in response rate, tumor shrinkage and survival. These results were so positive that Phase 3 trials have now started, this phase is known as registration intent and shows that the drugs are likely to enter the market.
The main parp inhibitors breast cancer which these new drugs target, is triple negative metastatic breast cancer, and in phase two the women treated with Poly (ADP � ribose) polymerase inhibitor BSI-201 in combination with usual chemotherapy had significantly better outcomes than women who received standard chemotherapy alone.
In the phase two of the parp study 62% of women had complete or partial responses and the disease stabilized, survival rate was also much higher in those treated with the parp inhibitors and breast cancer tumors shrunk. Phase Three of the drug owned by BiPar Sciences is said to be beginning this summer.
Where breast cancer has advanced to a stage beyond chemotherapy this treatment has been proven (to a phase two level) to be successful in treatment of women with metastatic breast cancer meaning their tumors do not express the hormones estrogen, progesterone or HER-2.